A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Conditions:   Asthma;   Severe Eosinophilic Asthma Interventions:   Drug: Symbicort®;   Drug: Fasenra®;   Drug: Ventolin® Sponsor:   AstraZeneca Not yet recruiting

Source: ClinicalTrials.gov - November 11, 2019 Category: Research Source Type: clinical trials